Innovation through M&A in the biopharmaceutical sector

Abstract

Purpose

This paper aims to review the latest management developments across the globe and pinpoint practical implications from cutting-edge research and case studies.

Design/methodology/approach

This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context.

Findings

Acquiring innovation will continue to be a necessity for pharmaceutical companies and to enjoy a sustainable advantage, they have the obligation to look for competitive advantage through coordination between both upstream and downstream capacities. A strict focus on the core competency of the enterprise is fast becoming obsolete.

Practical implications

The paper provides strategic insights and practical thinking that have influenced some of the world’s leading organizations.

Originality/value

The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent information and presenting it in a condensed and easy-to-digest format.

Citation

Amir-Aslani, A. and Chanel, M.A. (2016), "Innovation through M&A in the biopharmaceutical sector", Strategic Direction, Vol. 32 No. 6, pp. 27-29. https://doi.org/10.1108/SD-03-2016-0037